Park Place Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Park Place Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15K	Hold	4	–	–	﹤0.01%	1003
2026 Q1	$2.09K	Hold	4	–	–	﹤0.01%	752
2025 Q4	$2.33K	Hold	4	–	–	﹤0.01%	702
2025 Q3	$1.83K	Hold	4	–	–	﹤0.01%	715
2025 Q2	$1.2K	Hold	4	–	–	﹤0.01%	770
2025 Q1	$1.32K	Hold	4	–	–	﹤0.01%	764
2024 Q4	$1.23K	Hold	4	–	–	﹤0.01%	772
2024 Q3	$849	Hold	4	–	–	﹤0.01%	834
2024 Q2	$1.12K	Buy	+4	New	+$952	﹤0.01%	826

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Park Place Capital's MDGL Position: Q2 2026 in Review

Park Place Capital held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 4 shares worth $2.15K. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

Park Place Capital first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.33K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Park Place Capital held 4 shares of Madrigal Pharmaceuticals worth $2.15K as of Q2 2026.
Park Place Capital left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #1003 holding.
Park Place Capital first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Park Place Capital's Madrigal Pharmaceuticals position peaked at $2.33K in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.